Aurobindo Pharma announced that its wholly owned subsidiary, Eugia Pharma Specialities Limited, has launched Pomalidomide Capsules (1mg, 2mg, 3mg, and 4mg) in the US market. This product is the generic equivalent of Pomalyst® Capsules, and Eugia was a First-to-File (FTF) ANDA applicant. Pomalidomide is an important third-generation drug used to treat relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma. The US market for this drug is estimated at approximately US$ 3.3 billion.
Generic Launch in the US Market
Aurobindo Pharma Limited confirmed via a regulatory filing dated March 4, 2026, that its subsidiary, Eugia Pharma Specialities Limited, has successfully launched Pomalidomide Capsules in the United States. The product is available in four strengths: 1 mg, 2 mg, 3 mg, and 4 mg.
Product Details and Market Significance
The newly launched capsules are the generic equivalent of Pomalyst® Capsules, originally manufactured by BMS Pharmaceuticals Corp. Eugia Pharma secured a significant advantage by being one of the First-to-File (FTF) ANDA applicants for this product. The manufacturing operations for Pomalidomide Capsules will be conducted at Eugia Unit-I.
Market intelligence indicates that Pomalidomide Capsules represent a substantial commercial opportunity. According to IQVIA MAT data for the twelve months ending January 2026, the estimated market size for Pomalidomide Capsules in the U.S. reached approximately US$ 3.3 billion.
Therapeutic Application
Pomalidomide is classified as a third-generation immunomodulatory drug (IMID). It is clinically utilized in combination with dexamethasone (and sometimes bortezomib) to treat severe conditions, specifically relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma.
About Aurobindo Pharma Limited
Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercializes a diverse range of generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients across over 150 countries. The company maintains a robust compliance record, with 30+ manufacturing and packaging facilities approved by major global regulatory agencies, including the USFDA, UK MHRA, and Japan PMDA.
Source: BSE
